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EXTENDED ABSTRACT 
   Salmonella enterica has long been recognised as an 
important zoonotic pathogen of economic significance 
in animals and humans and remains the primary cause 
of reported food poisoning worldwide with massive 
outbreaks occurring in recent years. The most 
commonly serovars reported in human infections have 
been Enteritidis and Typhimurium, comprising 
respectively 76% and 14% of the cases in the EU while 
other serovars caused each 1% or less of the cases. 
Although many efforts have been done to prevent and 
control Salmonella Enteritidis, it is still a major cause of 
gastrointestinal disease in the EU and USA. 
Investigations of outbreaks and sporadic cases have 
repeatedly pointed out that the most common sources of 
S. Enteritidis infection are poultry and poultry 
derivatives. For this reason, controlling Salmonella 
infections has become an important goal for the poultry 
industry. 
   The use and misuse of antimicrobials in both humans 
and animals have given rise to the emergence of 
infectious bacteria displaying resistance toward many, 
and in some cases all, effective antimicrobials, turning 
difficult the treatment of both animals and humans. This 
has become a critical problem that limits the use of once 
widely used drugs. In recent years, an increasing 
number of Salmonellae isolates resistant to multiple 
antimicrobial agents has been identified. Thus, as many 
authors agree and pursue, development of alternatives to 
chemotherapy is imperative and a critical priority. The 
use of bacteriophages (phages), viruses that specifically 
infect and lyse bacteria, as a therapeutic agent (phage 
therapy) is one possible option for controlling 
pathogenic bacteria. Phages as bio-control agents for 
Salmonellae and other pathogens have already been 
tested with success showing some advantages over 
antibiotics. However, due to the high specificity of 
phages, they can only be produced in their natural hosts. 
Their replication in pathogenic hosts causes the release 
of cell debris and large quantities of both endotoxins 
and exotoxins are found in the crude phage lysate.  
   The use of a non-pathogenic host in the production 
process would eliminate the risk of accidentally 
administering a pathogen and the commitment of 100% 
efficiency in contaminants removal. Nevertheless, this 
tends to be a difficult or even impossible approach since 
ambivalent phages, especially those infecting both 
Salmonella and E. coli, are rare. 
   In this work, the previously isolated Salmonella phage 
PVP-SE1 (figure 1) belonging to the Myoviridae family 
showed the broadest lytic spectrum among all tested 
phages (table 1).  
 
Figure 1: TEM of phage PVP-SE1 
   Furthermore, besides being able to lyse several 
Salmonella isolates, it was also able to infect two 
isolates of E. coli (table 1) and thus phi PVP-SE1 can be 
considered a polyvalent phage. This characteristic is 
particularly fascinating since only a few phages with a 
relatively broad host range (with a host range over 
species borders) are known and such phages would be 
useful for therapeutic purposes. Moreover, this phage 
was able to infect more strains than Felix 01, which is 
known for its wide lytic spectrum among Salmonella 
being able to lyse up to 99.5% of Salmonella strains. 
   Due to its ability to lyse E. coli BL21 strain we study 
the possibility of producing PVP-SE1 in this non-
pathogenic alternative host. Although, the genome of a 
bacterial virus is always subject to host-controlled 
variation, a general phenomenon in which DNA may 
become modified when it is synthesized in one 
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cytoplasm and then undergo restriction upon entering 
another cytoplasm. Thus, the genotype of the host in 
which a virus reproduces affects the phenotype of the 
new formed virus progeny. In contrast to mutation, this 
phenomenon may be applied simultaneously to almost 
all the members of a developing phage population and 
generally is determined only by the nature of the last 
host in which the phage was replicated being 
independent of the previous phage history. 
Table 1: Lytic spectra of isolated Salmonella phages 
against the different Salmonella subtypes and other 
bacteria than Salmonella.  
Phage phi PVP-SE 1 2 3 
Strains       
Salmonella Typhimurium NCTC 12416 - subsp. I + - - 
Salmonella NCTC 13349 - subsp. I + + + 
Salmonella spp. SGSC 3047 - subsp. II + - - 
Salmonella spp. SGSC 3039 - subsp. II + - - 
Salmonella Arizonae SGSC 3063 - IIIa L - - 
Salmonella Arizonae 83 (isolate) - IIIa - - - 
Salmonella spp. SGSC 3069 - subsp. IIIb + - - 
Salmonella spp. SGSC 3068 - subsp. IIIb + - - 
Salmonella spp. SGSC 3086 - subsp. IV L - - 
Salmonella spp. SGSC 3074 - subsp. IV + - - 
Salmonella Bongori SGSC 3103 - subsp. V + - - 
Salmonella Bongori SGSC 3100 - subsp. V + - - 
Salmonella spp. SGSC 3118 - subsp. VI + - - 
Salmonella spp. SGSC 3116 - subsp. VI + - - 
Salmonella spp. SGSC 3121 - subsp. VII + - - 
Salmonella spp. SGSC 3120 - subsp. VII + - - 
Escherichia coli N9 L - - 
Escherichia coli N5 L - - 
Escherichia coli CECT 434 (ATCC 25922) L - - 
Escherichia coli BL21 + - - 
Escherichia coli K12 + - - 
Enterobacter amnigenes CECT 4078 (ATCC 
33072) L - - 
Enterobacter aerogenus CECT 684 (ATCC 13048) - - - 
Klebsiella pseudomonas 11296 - - - 
Shigella ATCC 12022 - - - 
Absence of phage halo and phage plaques (-); Presence of 
phage halo and phage plaques (+); Presence of phage halo and 
absence of phage plaques (L-Lysis from without). 
 
   In the present study the production of PVP-SE1 in the 
BL21 strain did not modify its lytic spectrum neither the 
phage DNA restriction profile (figure 2).  
 
 
Figure 2: Restriction profile of DNA of phage phi PVP-
SE1 produced in its natural host Salmonella Enteritidis 
(G0) and produced in the alternative host E. coli BL21 
(G6) digested with EcoRV. M (Marker) is a HindIII 
digest of lambda DNA. 
 
   These facts suggest that modifications were not 
induced in phage phi PVP-SE1 upon replication in a 
different host which supports the possibility of 
producing the phage in a non-pathogenic host 
contributing for the safety of a product based on this 
Salmonella biocontrol agent assuring this way its 
stability when used in phage therapy. Furthermore, the 
use of this non-pathogenic E. coli in phi PVP-SE1 
production will surely facilitate the production and 
purification processes by eliminating the risk of 
introducing a phage resistant pathogenic bacterium. The 
consequent reduction in costs and increased safety of 
the phage preparations will lead to an easier and faster 
approval of phage products for a wide diversity of 
commercial applications. 
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